NCT06667544View on ClinicalTrials.gov

A Study of RNK08954 in Subjects With Advanced Solid Tumors With KRAS ((Kirsten Rat Sarcoma) G12D Mutation

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

152

Participants

Timeline

Start Date

October 18, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

July 31, 2027

Conditions
KRAS G12D Mutation
Interventions
DRUG

RNK08954-01

Once daily oral treatment for a 3 week cycle

Trial Locations (6)

Unknown

RECRUITING

Guangxi Medical University Cancer Hospital, Nanning

RECRUITING

Henan Cancer Hospital, Zhengzhou

RECRUITING

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan

RECRUITING

Zhejiang Cancer Hospital, Hangzhou

RECRUITING

Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai

RECRUITING

Shanghai Chest Hospital, Shanghai

All Listed Sponsors
lead

Ranok Therapeutics (Hangzhou) Co., Ltd.

INDUSTRY